Investor's Business Daily on MSN

Gene editors, including powerhouse Beam Therapeutics, diverge on legal battle

Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded.
Small Business Trends on MSN

Zendesk expands AI employee services with Beams team acquisition

Discover how Zendesk enhances its AI employee services by acquiring beams, a move that promises to revolutionize workplace ...

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug ...

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program ...